{"id":"https://openalex.org/W4402566035","doi":"https://doi.org/10.1016/j.annonc.2024.08.1902","title":"1811TiP SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with SCLC, LCNEC and EP-NEC known to express DLL3","display_name":"1811TiP SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with SCLC, LCNEC and EP-NEC known to express DLL3","publication_year":2024,"publication_date":"2024-09-01","ids":{"openalex":"https://openalex.org/W4402566035","doi":"https://doi.org/10.1016/j.annonc.2024.08.1902"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2024.08.1902","doi":"https://doi.org/10.1016/j.annonc.2024.08.1902","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2024.08.1902","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(24)03421-5/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.annalsofoncology.org/article/S0923-7534(24)03421-5/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054580205","display_name":"Jacob M. Sands","orcid":"https://orcid.org/0000-0003-4663-7464","observed_orcids":["https://orcid.org/0000-0003-4663-7464"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Sands","raw_affiliation_strings":["Thoracic Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thoracic Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071560112","display_name":"Jason Timothy Henry","orcid":"https://orcid.org/0000-0003-1991-4227","observed_orcids":["https://orcid.org/0000-0003-1991-4227"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Henry","raw_affiliation_strings":["Research, Sarah Cannon Research Institute, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research, Sarah Cannon Research Institute, Nashville, TN, USA","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025951912","display_name":"Catherine Belle Meador","orcid":"https://orcid.org/0000-0001-5006-3569","observed_orcids":["https://orcid.org/0000-0001-5006-3569"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Meador","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067565930","display_name":"A.I. Spira","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Spira","raw_affiliation_strings":["Research Department, NEXT Virginia, Fairfax, VA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Department, NEXT Virginia, Fairfax, VA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101638085","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-7129-5593","observed_orcids":["https://orcid.org/0000-0002-7129-5593"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Mahadevan","raw_affiliation_strings":["Division of Hematology and Medical Oncology, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008084770","display_name":"G. McGregor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. McGregor","raw_affiliation_strings":["Clinical Development, Phanes Therapeutics, Inc., San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Phanes Therapeutics, Inc., San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032955590","display_name":"Rita Laeufle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Laeufle","raw_affiliation_strings":["Clinical Development, Phanes Therapeutics, Inc., San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Phanes Therapeutics, Inc., San Diego, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000228105","display_name":"Heng Zou","orcid":"https://orcid.org/0000-0002-3683-7916","observed_orcids":["https://orcid.org/0000-0002-3683-7916"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Zou","raw_affiliation_strings":["Clinical Development, Phanes Therapeutics, Inc., San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Phanes Therapeutics, Inc., San Diego, CA, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4600,"currency":"USD","value_usd":4600},"apc_paid":null,"fwci":0.1714,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.51893437,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"35","issue":null,"first_page":"S1073","last_page":"S1074"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.7764000296592712,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.7764000296592712,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.17569999396800995,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.023900000378489494,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.8859999775886536},{"id":"https://openalex.org/keywords/dll3","display_name":"DLL3","score":0.9020000100135803},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.9679999947547913},{"id":"https://openalex.org/keywords/large-cell-neuroendocrine-carcinoma","display_name":"large cell neuroendocrine carcinoma","score":0.9589999914169312},{"id":"https://openalex.org/keywords/neuroendocrine-carcinoma","display_name":"neuroendocrine carcinoma","score":0.9340000152587891},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6209999918937683},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5889999866485596},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.8330000042915344},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7250000238418579},{"id":"https://openalex.org/keywords/dose-expansion","display_name":"dose expansion","score":0.6819999814033508},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.956744909286499},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.7876697182655334},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5847128629684448},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4607582688331604},{"id":"https://openalex.org/C3019800554","wikidata":"https://www.wikidata.org/wiki/Q3813242","display_name":"Open label","level":3,"score":0.4602810740470886},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.4420347511768341},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43530434370040894},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.3385908007621765},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1885024607181549},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1525173783302307},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.1461266279220581},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.07328858971595764},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.05295315384864807}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2024.08.1902","doi":"https://doi.org/10.1016/j.annonc.2024.08.1902","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2024.08.1902","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(24)03421-5/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2024.08.1902","doi":"https://doi.org/10.1016/j.annonc.2024.08.1902","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2024.08.1902","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(24)03421-5/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320309466","display_name":"Medpace","ror":"https://ror.org/05mgcmd27"},{"id":"https://openalex.org/F4320309577","display_name":"Array BioPharma","ror":"https://ror.org/018axtd57"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320311653","display_name":"Taiho Pharmaceutical","ror":"https://ror.org/02v50dx14"},{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"},{"id":"https://openalex.org/F4320316635","display_name":"Constellation Pharmaceuticals","ror":"https://ror.org/04dxbz091"},{"id":"https://openalex.org/F4320317302","display_name":"Boehringer Ingelheim Japan","ror":"https://ror.org/02r1d7x68"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320318991","display_name":"Compass Therapeutics","ror":"https://ror.org/05nhdv432"},{"id":"https://openalex.org/F4320319071","display_name":"Moderna","ror":"https://ror.org/01xm4wg91"},{"id":"https://openalex.org/F4320319840","display_name":"Coherus Biosciences","ror":"https://ror.org/00mjj2d85"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320323316","display_name":"Shionogi","ror":"https://ror.org/01v3bqg10"},{"id":"https://openalex.org/F4320324177","display_name":"Otsuka Pharmaceutical","ror":"https://ror.org/013k5y296"},{"id":"https://openalex.org/F4320324309","display_name":"Japanese Society of Medical Oncology","ror":"https://ror.org/03fz8dh89"},{"id":"https://openalex.org/F4320327845","display_name":"Ono Pharmaceutical","ror":"https://ror.org/022jefx64"},{"id":"https://openalex.org/F4320328823","display_name":"Betta Pharmaceuticals","ror":"https://ror.org/00tf10278"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332200","display_name":"EMD Serono","ror":"https://ror.org/027zrs220"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"},{"id":"https://openalex.org/F4320333002","display_name":"Pfizer Japan","ror":"https://ror.org/05pm71w80"},{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"},{"id":"https://openalex.org/F4320333624","display_name":"Eli Lilly Japan","ror":"https://ror.org/01sv7f575"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320333871","display_name":"Bayer Yakuhin","ror":"https://ror.org/05arv2073"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4402566035.pdf","grobid_xml":"https://content.openalex.org/works/W4402566035.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4410816055","https://openalex.org/W7155094865","https://openalex.org/W4400272708","https://openalex.org/W4379283850","https://openalex.org/W4366768944","https://openalex.org/W4281685124","https://openalex.org/W4388045893","https://openalex.org/W7138336819","https://openalex.org/W4281694862","https://openalex.org/W4323024678"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-09-18T00:00:00"}